Dapsone: a steroid-sparing drug for refractory immunoglobulin A vasculitis?
Open Access
- 15 May 2020
- journal article
- editorial
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 63 (5), 178-179
- https://doi.org/10.3345/cep.2019.01634
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Treatment of refractory IgA vasculitis with dapsone: a systematic reviewClinical and Experimental Pediatrics, 2020
- Use of Dapsone in the Treatment of Chronic Idiopathic and Autoimmune UrticariaJAMA Dermatology, 2019
- Rituximab treatment for chronic steroid-dependent Henoch-Schonlein purpura: 8 cases and a review of the literaturePediatric Rheumatology, 2018
- Dapsone-induced agranulocytosis in patients with Hansen's diseaseAnais Brasileiros de Dermatologia, 2017
- Characteristics and Management of IgA Vasculitis (Henoch‐Schönlein) in Adults: Data From 260 Patients Included in a French Multicenter Retrospective SurveyArthritis & Rheumatology, 2017
- Features and Treatment of Dapsone-Induced Hepatitis, Based on Analysis of 44 Cases and Literature ReviewClinical Gastroenterology and Hepatology, 2017
- Dapsone in dermatology and beyondArchiv für dermatologische Forschung, 2013
- Henoch–Schönlein purpura in childrenJournal of Paediatrics and Child Health, 2013
- Severe dapsone hypersensitivity syndrome in a childKorean Journal of Pediatrics, 2013
- EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteriaAnnals Of The Rheumatic Diseases, 2010